Regulus Therapeutics reported $175K in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US USD 41.08M 1.52M
Biogen BIIB:US USD 59.9M 5.9M
Gilead Sciences GILD:US USD 229M 13M
Intercept Pharmaceuticals ICPT:US USD 5.24M 1.43M
Intrexon XON:US USD 2.04M 27K
IONIS PHARMACEUT IONS:US USD 2.14M 9K
Merk MRK:US USD 244M 4M
Omeros OMER:US USD 4.93M 5K
Regulus Therapeutics RGLS:US USD 175K 13K
YTE INCY:US USD 641K 37K